ZIVO Bioscience Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

John Payne

Chief executive officer

US$400.0k

Total compensation

CEO salary percentage	100.0%
CEO tenure	2.3yrs
CEO ownership	0.06%
Management average tenure	no data
Board average tenure	10.2yrs

Recent management updates

Recent updates

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Nov 25

CEO Compensation Analysis

How has John Payne's remuneration changed compared to ZIVO Bioscience's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$400k	US$400k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$848k	US$398k	-US$9m
Sep 30 2022	n/a	n/a	-US$9m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$689k	n/a	-US$9m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$1m	n/a	-US$9m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$11m
Dec 31 2019	US$49k	n/a	-US$12m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$13m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$87k	n/a	-US$15m
Sep 30 2018	n/a	n/a	-US$15m
Jun 30 2018	n/a	n/a	-US$14m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	US$43k	n/a	-US$10m

Compensation vs Market: John's total compensation ($USD400.00K) is below average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Payne (75 yo)

2.3yrs

Tenure

US$400,000

Compensation

Mr. John B. Payne serves as President, Chief Executive Officer and Chairman of the Board at ZIVO Bioscience, Inc. since January 7, 2022. He is the Chairman, Chief Executive Officer and President of COMPASS...

Board Members

Name	Position	Tenure	Compensation	Ownership
John Payne	President	10.8yrs	US$400.00k	0.056% $ 12.4k
Nola Masterson	Independent Director	9.7yrs	US$106.06k	0.031% $ 6.9k
Christopher Maggiore	Independent Director	10.8yrs	US$103.82k	12.67% $ 2.8m
Alison Cornell	Lead Independent Director	3.3yrs	US$112.79k	2.45% $ 542.5k

10.2yrs

Average Tenure

67.5yo

Average Age

Experienced Board: ZIVO's board of directors are seasoned and experienced ( 10.2 years average tenure).

ZIVO Bioscience Management

Management criteria checks 3/4

Key information

Recent management updates

ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Independent Director recently bought US$72k worth of stock

ZIVO Bioscience, Inc., Annual General Meeting, Jul 28, 2022

Independent Director recently bought US$340k worth of stock

ZIVO Bioscience, Inc. Appoints Alison A. Cornell as Member of the Board

ZIVO Bioscience, Inc. Announces Executive Changes

Recent updates

ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024

The Nasdaq Stock Market to Delist the Common Stock of ZIVO Bioscience

ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

New major risk - Share price stability

ZIVO Bioscience Announces Reverse Stock Split to Regain Compliance with the Nasdaq Stock Market’s Continued Listing Requirements

New major risk - Market cap size

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Nasdaq Hearings Panel Grants Zivo Biosciences's Request to Provide an Extension Until November 20, 2023 to Regain Compliance with the Stockholders’ Equity Rule for Continued Listing on Nasdaq

New minor risk - Shareholder dilution

Zivo Bioscience, Inc. Announces its GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as Human Food Ingredient

Nasdaq Notifies Zivo Biosciences Regarding its Common Stock Delisting from Nasdaq Due to Non-Compliance with the Stockholders’ Equity Requirement

ZIVO Bioscience, Inc. Announces Results of Study with Its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Independent Director recently bought US$72k worth of stock

Zivo Bioscience Receives Written Notice from the Nasdaq Stock Market

ZIVO Bioscience, Inc. Reports USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

ZIVO Bioscience, Inc., Annual General Meeting, Jul 28, 2022

ZIVO Bioscience Regains Compliance Following Receipt of Non-Compliance Notice from Nasdaq

ZIVO Bioscience, Inc. announced delayed annual 10-K filing